Porosome Therapeutics

Porosome Therapeutics is a private, preclinical-stage biotech founded in 2018 and based in San Diego. The company's core platform is built upon the foundational discovery of the porosome, a nanomachine responsible for cellular secretion, which it aims to structurally elucidate and therapeutically modulate using an integrated cryo-EM and AI approach. Its lead programs target the underlying secretory dysfunction in Alzheimer's disease and cystic fibrosis, proposing a novel mechanism beyond current standards of care. The company is pre-revenue and positioned at the intersection of structural biology, AI-driven drug discovery, and nanomachine therapeutics.

Integrated platform combining cryo-electron microscopy (cryo-EM) and artificial intelligence (AI) to solve the atomic structure and assembly of the 'porosome' (cellular secretory nanomachine). Enables targeted small molecule design to correct secretory defects and a proprietary approach for introducing functional porosomes into cells.

In Alzheimer's, competes against large pharma and biotechs targeting amyloid, tau, inflammation, and other pathways. In cystic fibrosis, faces established CFTR modulator therapies but aims to address residual secretory defects in non-responders. Its unique nanomachine-focused approach is a key differentiator but is unvalidated.